---
schema_version: "secwatch.filing_event.v1"
accession: "0001655759-25-000098"
form_type: "8-K"
ticker: "ARVN"
cik: "0001655759"
company_name: "ARVINAS, INC."
filed_at: "2025-06-06T23:59:59+00:00"
generated_at: "2026-05-19T18:25:18.806751+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Arvinas submits NDA to FDA for vepdegestrant in ER+/HER2- ESR1-mutated breast cancer

## Summary
- NDA supported by pivotal Phase 3 VERITAC-2 trial results presented at ASCO 2025 and published in NEJM.
- Vepdegestrant is a first-in-class PROTAC ER degrader; fast track designation granted by FDA.
- If approved, vepdegestrant would be first FDA-approved PROTAC ER degrader for advanced breast cancer.
- Jointly developed with Pfizer (PFE); NDA covers ER+/HER2- ESR1-mutated advanced/metastatic breast cancer.
- VERITAC-2 enrolled 624 patients across 25 countries; primary endpoint PFS in ESR1-mutation and ITT populations.

## SEC filing metadata
- accession: 0001655759-25-000098
- form_type: 8-K
- ticker: ARVN
- cik: 0001655759
- company_name: ARVINAS, INC.
- filed_at: 2025-06-06T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1655759/000165575925000098/0001655759-25-000098-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1655759/000165575925000098/arvn-20250606.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001655759-25-000098
- JSON: https://secwatch.observer/filing/0001655759-25-000098.json
- Plain text: https://secwatch.observer/filing/0001655759-25-000098.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.